Skip to content 
Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property theft, as well as financial crimes, including those involving cryptocurrency. It also offers Inseyets, digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations; Guardian Forensics, an evidence management solution which enables customers to manage their digital forensics workflows, and to store, share and review digital evidence; Guardian Collaborate, a digital evidence sharing tool; and Guardian Investigate, a case management and AI-powered analytics solution. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence and enables actionable insights into a range of crime types; Corellium Falcon for conducting mobile vulnerability research, exploit introspection, and malware analysis; and Corellium Viper for mobile application penetration testing capabilities. Further, the company offers professional services, such as training and certification services, and advanced services. It serves federal, state, and local agencies, as well as corporations and service providers. The company is headquartered in Petah Tikva, Israel. more
| Time Frame | CLBT | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -3.03% | -2.39% | -0.8% |
| 1-Month Return | 2.07% | -4.76% | -5.34% |
| 3-Month Return | -23.57% | -7.69% | -4.72% |
| 6-Month Return | -25.63% | -5.7% | -2.42% |
| 1-Year Return | -29.08% | 28.73% | 16.28% |
| 3-Year Return | 126.27% | 76.01% | 58.89% |
| 5-Year Return | 40.04% | 100.14% | 64.03% |
| 10-Year Return | 42.65% | 499.19% | 216.9% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 246.25M | 270.65M | 325.11M | 401.20M | 475.68M | [{"date":"2021-12-31","value":51.77,"profit":true},{"date":"2022-12-31","value":56.9,"profit":true},{"date":"2023-12-31","value":68.35,"profit":true},{"date":"2024-12-31","value":84.34,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Cost of Revenue | 42.56M | 50.75M | 53.23M | 62.59M | 75.17M | [{"date":"2021-12-31","value":56.61,"profit":true},{"date":"2022-12-31","value":67.51,"profit":true},{"date":"2023-12-31","value":70.81,"profit":true},{"date":"2024-12-31","value":83.27,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Profit | 203.69M | 219.91M | 271.88M | 338.61M | 400.50M | [{"date":"2021-12-31","value":50.86,"profit":true},{"date":"2022-12-31","value":54.91,"profit":true},{"date":"2023-12-31","value":67.88,"profit":true},{"date":"2024-12-31","value":84.55,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Margin | 82.72% | 81.25% | 83.63% | 84.40% | 84.20% | [{"date":"2021-12-31","value":98.01,"profit":true},{"date":"2022-12-31","value":96.27,"profit":true},{"date":"2023-12-31","value":99.09,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":99.76,"profit":true}] |
| Operating Expenses | 189.87M | 218.86M | 238.64M | 281.70M | 334.02M | [{"date":"2021-12-31","value":56.84,"profit":true},{"date":"2022-12-31","value":65.52,"profit":true},{"date":"2023-12-31","value":71.44,"profit":true},{"date":"2024-12-31","value":84.34,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Operating Income | 13.82M | 1.04M | 33.24M | 56.91M | 66.48M | [{"date":"2021-12-31","value":20.79,"profit":true},{"date":"2022-12-31","value":1.57,"profit":true},{"date":"2023-12-31","value":50,"profit":true},{"date":"2024-12-31","value":85.6,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Total Non-Operating Income/Expense | 136.97M | 239.43M | (191.67M) | (664.43M) | 47.66M | [{"date":"2021-12-31","value":57.2,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-80.05,"profit":false},{"date":"2024-12-31","value":-277.5,"profit":false},{"date":"2025-12-31","value":19.91,"profit":true}] |
| Pre-Tax Income | 82.31M | 120.76M | (75.56M) | (275.98M) | 90.68M | [{"date":"2021-12-31","value":68.16,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-62.57,"profit":false},{"date":"2024-12-31","value":-228.54,"profit":false},{"date":"2025-12-31","value":75.09,"profit":true}] |
| Income Taxes | 10.91M | (45.00K) | 5.54M | 7.02M | 12.35M | [{"date":"2021-12-31","value":88.32,"profit":true},{"date":"2022-12-31","value":-0.36,"profit":false},{"date":"2023-12-31","value":44.83,"profit":true},{"date":"2024-12-31","value":56.86,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Income After Taxes | 71.40M | 120.81M | (81.10M) | (283.01M) | 78.33M | [{"date":"2021-12-31","value":59.1,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-67.13,"profit":false},{"date":"2024-12-31","value":-234.27,"profit":false},{"date":"2025-12-31","value":64.84,"profit":true}] |
| Income From Continuous Operations | 71.40M | 120.81M | (59.38M) | (283.01M) | 78.33M | [{"date":"2021-12-31","value":59.1,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-49.15,"profit":false},{"date":"2024-12-31","value":-234.27,"profit":false},{"date":"2025-12-31","value":64.84,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 71.40M | 120.81M | (81.10M) | (283.01M) | 78.33M | [{"date":"2021-12-31","value":59.1,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-67.13,"profit":false},{"date":"2024-12-31","value":-234.27,"profit":false},{"date":"2025-12-31","value":64.84,"profit":true}] |
| EPS (Diluted) | 0.38 | 0.27 | 0.29 | 0.42 | 0.44 | [{"date":"2021-12-31","value":86.36,"profit":true},{"date":"2022-12-31","value":61.36,"profit":true},{"date":"2023-12-31","value":65.91,"profit":true},{"date":"2024-12-31","value":95.45,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| CLBT | |
|---|---|
| Cash Ratio | 1.18 |
| Current Ratio | 1.56 |
| Quick Ratio | 1.54 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| CLBT | |
|---|---|
| ROA (LTM) | 5.10% |
| ROE (LTM) | 19.10% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| CLBT | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.48 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.52 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| CLBT | |
|---|---|
| Trailing PE | 42.68 |
| Forward PE | 35.71 |
| P/S (TTM) | 6.94 |
| P/B | 6.81 |
| Price/FCF | 42 |
| EV/R | 6.07 |
| EV/Ebitda | 28.00 |
Cellebrite DI (CLBT) share price today is $13.895
Yes, Indians can buy shares of Cellebrite DI (CLBT) on Vested. To buy
Yes, you can purchase fractional shares of Cellebrite DI (CLBT) via the Vested app. You can start investing in Cellebrite DI (CLBT) with a minimum investment of $1.
You can invest in shares of Cellebrite DI (CLBT) via Vested in three simple steps:
The 52-week high price of Cellebrite DI (CLBT) is $20.53. The 52-week low price of Cellebrite DI (CLBT) is $11.76.
The price-to-earnings (P/E) ratio of Cellebrite DI (CLBT) is 42.6774
The price-to-book (P/B) ratio of Cellebrite DI (CLBT) is 6.81
The dividend yield of Cellebrite DI (CLBT) is 0.00%
The market capitalization of Cellebrite DI (CLBT) is $3.44B
The stock symbol (or ticker) of Cellebrite DI is CLBT
Consider the share price of Cellebrite DI as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Cellebrite DI has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Cellebrite DI shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Cellebrite DI stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Cellebrite DI and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Cellebrite DI stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
